Sharesmagazine
 Home   Log In   Register   Our Services   My Account   Contact   Help 
 Stockwatch   Level 2   Portfolio   Charts   Share Price   Awards   Market Scan   Videos   Broker Notes   Director Deals   Traders' Room 
 Funds   Trades   Terminal   Alerts   Heatmaps   News   Indices   Forward Diary   Forex Prices   Shares Magazine   Investors' Room 
 CFDs   Shares   SIPPs   ISAs   Forex   ETFs   Comparison Tables   Spread Betting 
You are NOT currently logged in
 
Register now or login to post to this thread.
  • Page:
  • 1
  • 2

Midatech Pharma (MTPH)     

dreamcatcher - 05 Jan 2015 17:23



Midatech is a nanomedicine company focused on the development and commercialisation of multiple, high-value, targeted therapies for major diseases with unmet medical need.


Midatech is advancing a pipeline of novel clinical and pre-clinical product candidates based on its proprietary drug conjugate and sustained release delivery platforms with a clear focus on the key therapeutic areas of diabetes, cancer and ophthalmology. Midatech’s strategy is to develop its products in-house in rare cancers and with partners in other indications, and to accelerate growth of its business through strategic acquisition of complementary products and technologies.

Midatech’s shares are traded on the Alternative Investment Market (AIM) of the London Stock Exchange under the ticker symbol MTPH (ISIN number GB00BRTL9B63).

Admission and First Day of Dealings on 8 December 2014

Major shareholders
http://www.midatechpharma.com/investors/share-information


http://www.midatechpharma.com/

Chart.aspx?Provider=EODIntra&Code=MTPH&SChart.aspx?Provider=EODIntra&Code=MTPH&S

dreamcatcher - 06 Mar 2015 07:09 - 8 of 23

Research Collaboration Signed with Global Pharma
RNS
RNS Number : 7141G
Midatech Pharma PLC
06 March 2015

6 March 2015



Midatech Pharma PLC

("Midatech", the "Company" or the "Group")



Research Collaboration Signed with Global Pharmaceutical Company



Midatech Pharma (AIM: MTPH), the international specialty pharmaceutical with a diversified portfolio of high-value assets, today announces the signature of a new research collaboration between MidaSol™ Therapeutics LP, a strategic joint venture between Midatech with MonoSol Rx LLC, and a major international pharmaceutical company (the "Partner").



Under the terms of the collaboration, MidaSol and the Partner will evaluate the preclinical effectiveness of MidaSol's gold-nanoparticle (GNP) and PharmaFilm® transbuccal (via the inside cheek) strip technologies for the needle-free delivery of an existing marketed diabetes drug for the Partner. The terms include an upfront payment, and several performance-driven milestones, details of which remain confidential. The project has a six-month term.



Commenting on the collaboration, Dr Jim Philips, CEO of Midatech Pharma, said: "This collaboration demonstrates the growing interest in the application of our GNP drug-conjugate technology with a range of therapeutic compounds for effective needle-free treatment. We aim to commercialise such products and ones in our own pipeline through partnerships and licensing opportunities and this agreement demonstrates the continuing successful implementation of our strategy."



Keith Kendall, CEO of MonoSol Rx, said: "The agreement we have signed with a major pharmaceutical company highlights the value of our joint venture with Midatech and the growing interest in needle-free products. We will now work alongside our new partner to progress this product through development with the goal of delivering it to diabetic patients around the world."

dreamcatcher - 06 Mar 2015 15:27 - 9 of 23

UPDATE - Midatech Pharma's collaboration agreement "provides significant risk mitigation"

By John Harrington

March 06 2015, 2:33pm
The broker speculates that the unnamed partner could be Lilly, AstraZeneca or Sanof


Nanomedicine specialist Midatech Pharma (LON:MTPH) is to work with a global pharmaceutical company on ways to deliver a diabetes treatment without recourse to injections.

The tie-up will be effected through MidaSol, a joint venture (JV) between Midatech and US firm MonoSol Rx. The JV is developing a strip that slowly dissolves in the mouth to rapidly deliver insulin.

Potentially more effective and faster acting than the other non-injected forms of the medication, it provides a painless, easy to use alternative to pumps and needles.

The unnamed major pharmaceuticals company already has a treatment for diabetes, but it is interested in learning whether MidaSol's gold-nanoparticle (GNP) and PharmaFilm oral strip technologies can effectively deliver the drug without users having to get the needle.

The terms of the collaboration agreement announced on Friday include an upfront payment, and several performance-driven milestones, details of which remain confidential. The project has a six-month term.

Speaking to Proactive Investors, Dr Jim Philips, chief executive officer (CEO) of Midatech, said it is the company's second agreement with a large pharmaceutical company in the diabetes area.

"This collaboration demonstrates the growing interest in the application of our GNP drug-conjugate technology with a range of therapeutic compounds for effective needle-free treatment," Dr Philips said in a stock market announcement.

"We aim to commercialise such products and ones in our own pipeline through partnerships and licensing opportunities and this agreement demonstrates the continuing successful implementation of our strategy" he added.

Keith Kendall, CEO of MonoSol Rx, said: "We will now work alongside our new partner to progress this product through development with the goal of delivering it to diabetic patients around the world."

Dr Philips told Proactive Investors that the most important thing for these types of collaborations is that they are validating Midatech's technologies.

"It's about proving they are commercially viable to partners, as well as our own internal programmes.

"Every time we add a revenue earning partnership it obviously helps us achieve our revenue growth projections and give us more potential upside in the future through licensing deals.

"The more products that use our technology at the end of the day, the more revenue we'll earn in the future," Dr Philips explained.

The growing obesity epidemic means the diabetes market is a huge one valued at an estimated US$40bn, and it is expanding rapidly.

The insulin product is the most advanced in the portfolio of Midatech, which floated at the end of 2014, and is set to enter phase-II clinical trials later this year.

Shares in Midatech were up 13.5p to 313.5p in mid-afternoon trading.

Panmure Gordon has initiated coverage of Midatech with a 420p price target, and described today's news as an exciting collaboration that significantly mitigates risk in the firm's entire diabetes franchise.

The broker speculates that the unnamed partner could be Lilly, AstraZeneca or Sanofi.

"At this stage, we view this collaboration as modest income generating whilst the pre-clinical feasibility is on-going," the broker said, as it stressed that treatment of diabetes represents just one strong on Midatech's bow.

"The main therapeutic focus includes diabetes, oncology, neurology and ophthalmologic conditions with a combined addressable market of more than US$90bn," the broker said. "The nano-pharmaceutical market itself is already worth some US$7bn+."

Panmure Gordon predicts the growth plans will receive a turbo boost from mergers & acquisitions activity.

"CEO Jim Phillips and chairman Rolf Stahel in particular have an excellent track record in pharmaceutical ‘buy and build’. Its relatively early-stage nature offers significant upside for investors.

"Capital raised should help with licensing deals, and also provide a realistic time frame for the company to become profitable and cash-generative. Phase IIa data from its insulin product is expected in H2 2015," noted analyst Savvas Neophytou.

dreamcatcher - 06 Mar 2015 18:00 - 10 of 23

Shares - Drug delivery specialist Midatech Pharma expects to report the first hard evidence its diabetes-controlling insulin strip works in the third quarter. This is just one of 12 products in the pipeline that focuses on the targeted delivery or controlled release of existing treatments. If regulators approve the strip in the coming years following the three-stage clinical trial process it could be the first non -injectable insulin treatment launched into what the company estimates is a $10 billion market.

dreamcatcher - 12 Apr 2015 17:35 - 11 of 23

Finals Friday 17 April

dreamcatcher - 14 Apr 2015 19:29 - 12 of 23

Midatech Pharma inks new deal with leading US cancer centre

By Ian Lyall

April 14 2015, 7:47am
There is a significant unmet medical need currently as glioblastoma is difficult to combat given the given the different cell types at play.
There is a significant unmet medical need currently as glioblastoma is difficult to combat given the given the different cell types at play.


Midatech Pharma (LON:MTPH) said it has inked a new collaboration with the America’s Dana-Farber Cancer Institute to test the pre-clinical effectiveness of its nano-medicines in the brain tumour glioblastoma.

The aim of the tie-up with this world leading research group, which is a teaching affiliate of the Harvard Medical School, is to find most effective targeted treatments as quickly as possible.

There is a significant unmet medical need currently as glioblastoma is difficult to combat given the given the different cell types at play.

Chief executive, Dr Jim Philips, said: "This collaboration demonstrates the growing interest in our technology across a range of therapeutic compounds and for specifically targeting certain types of cancer cells.

“Glioblastoma is a very common but hard to treat brain cancer condition with poor survival rates.

“Our goal is to develop an effective treatment that transforms patient outcomes via our collaboration with Dana-Farber."

Midatech has two platforms – a carbohydrate-coated gold nanoparticle and its sustained release system. Both are about getting medicines to the right place in the right quantities at the right time.

The company’s gold nano-particles, or GNPs for short, promise a revolution in targeted therapies for cancer.

To radically simplify the process deployed these GNPs act as guided missiles.

In treating cancer with traditional chemo-therapy, for instance, they are programmed to hit ONLY a specific tumour type with their payload.

This highly targeted approach allows physicians to potentially administer lower doses and it also means there is little collateral damage.

Its Q-Sphera technology works in a different way to deliver the drug at the right time.

It is a sustained release platform and has adopted 3D and ink jet printing techniques to create particles that dissolve in a certain way over a certain time-scale.

dreamcatcher - 17 Apr 2015 16:01 - 13 of 23

Preliminary Results
RNS
RNS Number : 5030K
Midatech Pharma PLC
17 April 2015

17 April 2015



Midatech Pharma PLC

("Midatech", the "Company" or the "Group")



Preliminary results for the year ending 31 December 2014



- Transformational year including IPO, acquisition of Q Chip, collaboration agreement and EU manufacturing grant



Midatech Pharma plc (AIM: MTPH), the international specialty pharmaceutical company with a diversified portfolio of high-value assets, today announces its maiden audited preliminary results for the twelve month period ended 31 December 2014.



Operational Highlights (including post-period end)

· Awarded a €7.9m Horizon 2020 European Union grant (€3.4m direct to the Group) to fund manufacturing scale-up - September 2014

· Acquisition of Q Chip Limited ("Q Chip") bringing complementary technology and products, enabling sustained release over extended periods of time - December 2014

· Positive results achieved in proof-of-concept OpsiSporin study with sustained release treatment for uveitis (ocular inflammation) - February 2015

· Research collaboration agreement signed with unnamed global pharmaceutical company in field of diabetes - March 2015

· Appointment of Nick Robbins-Cherry, Finance Director in February 2014 and Dr Craig Cook, Chief Operating Officer in January 2014

· Research collaboration agreement signed with Dana-Farber Cancer Institute - April 2015



Financial Highlights

· Oversubscribed flotation on the AIM market of the London Stock Exchange in December 2014 raising £32.0m (before expenses)

· Combined proforma revenue ahead of expectations at £0.73m

· Strong balance sheet with £30.33m cash and deposits at 31 December 2014 (2013: £2.39m)

· Net loss after tax of £7.38m (2013: £4.08m) with net cash inflow in the year of £27.94m (2013: £2.25m)

· Tax credit receivable of £0.84m (2013: £0.80m)



Commenting on the maiden preliminary results, Dr Jim Philips, CEO of Midatech, said: "2014 was a transformational year for Midatech Pharma. Our goal is to build Midatech into a world-leading international specialty pharmaceutical company with a diversified portfolio of high-value assets and we are well on our path to achieving this.



"Our growth strategy is based on the maturation of our technology platforms, a clear focus on the key therapeutic areas within our pipeline and on the delivery of strategic later stage product focussed acquisitions.



"I would like to thank all of our staff and investors for their support and I look forward to leading Midatech through the next stages of its corporate development."

dreamcatcher - 04 Jun 2015 12:02 - 14 of 23

Proposed Acquisition of DARA BioSciences, Inc.

http://www.moneyam.com/action/news/showArticle?id=5050221

dreamcatcher - 04 Jun 2015 12:07 - 15 of 23

4 Jun Panmure Gordon 420.00 Buy

dreamcatcher - 23 Jul 2015 11:44 - 16 of 23

Initiation of Phase IIa study of insulin delivery
RNS
RNS Number : 8362T
Midatech Pharma PLC
23 July 2015

23 July 2015



Midatech Pharma PLC

("Midatech" or the "Company")



Initiation of Phase IIa study of insulin delivery via buccal strip for type 1 diabetes



Midatech (AIM: MTPH), the international specialty pharmaceutical company with a diversified portfolio of high-value products in development, in partnership with MonoSol Rx, today announces that the first patient has been treated in a Phase IIa open label, cross-over, seven arm study of Insulin Buccal Soluble Film (MSL-001) for type 1 diabetes mellitus.



The objectives of the study are to establish the pharmacodynamic and pharmacokinetic profile, and safety and tolerability of MSL-001 (MidaForm® Insulin PharmFilm®) in comparison to subcutaneous administered human recombinant insulin (Humulin®).



The study is being conducted in Perth, Australia, with a total of 12 patients, male and female, aged 18 - 55 being treated from a screening pool of up to 35 subjects. The overall study duration is approximately five months.



MSL-001 contains recombinant human insulin which is non-covalently bound to glycan-coated gold nanoparticles and embedded in an oral, muco-adhesive, polymeric film for transbuccal delivery. The drug was invented by Midatech and MonoSol Rx and is being developed by the parties' joint venture, MidaSol Therapeutics.



Commenting on the study, Dr. Jim Philips, CEO of Midatech Pharma, said: "Diabetes incidence is forecast to hit 500m people, globally, by 2025; with our partnered transbuccal insulin strip, MSL-001 is targeting a $20 billion market, adding significant revenue potential to our growing portfolio of products."



- Ends -



dreamcatcher - 12 Aug 2015 15:15 - 17 of 23

Filing of Form F-4 Registration Statement with SEC
RNS
RNS Number : 7745V
Midatech Pharma PLC
12 August 2015

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN OR INTO OR FROM THE UNITED STATES OR ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION



12 August 2015



Midatech Pharma PLC

("Midatech" or the "Company")



Filing of Form F-4 Registration Statement with SEC





Midatech Pharma (AIM: MTPH), the international specialty pharmaceutical company with a diversified portfolio of high-value products in development, today announced that it has filed with the United States Securities and Exchange Commission its Registration Statement on Form F-4 in connection with its previously announced offer for DARA BioSciences Inc.



Included within the Form F-4 are references to Midatech's Q1 2015 financial information, not previously disclosed, and an updated set of financial statements for the year ended 31 December 2014. Notes referenced therein detail that one of the intangible assets acquired with Midatech Pharma (Wales) Limited (formerly Q Chip Limited) has become impaired. This was as a result of further information of which the Board became aware subsequent to the approval of the 2014 statutory accounts, resulting in a £1.8m non-cash charge which will be restated in the opening balance sheet of the December 2015 statutory financial statements.



Included within the Midatech Group financial statements to 31 March 2015 are the following headlines:

· Revenue of £39,000

· Loss from operations of £2.674 million

· Total equity less liabilities of £39.298 million



This submission is subject to review and comment by the SEC, and may be revised further as necessary. The filed Form F-4 can be viewed on Midatech's website: www.midatechpharma.com/investors/reports-and-presentations



Commenting on the announcement, Dr. Jim Philips, CEO of Midatech Pharma, said: The submission of this filing demonstrates further positive progress towards the acquisition of DARA and, ultimately, brings Midatech closer towards developing our target therapeutic area of oncology as an international specialty pharma.



"It is also of note that the Q Chip acquisition is delivering significant product opportunities and value through the development of the Q Octreo and OpsiSporin programmes."



- Ends -

dreamcatcher - 12 Aug 2015 15:16 - 18 of 23

12 Aug Panmure Gordon 420.00 Buy

dreamcatcher - 13 Aug 2015 11:56 - 19 of 23

Ocular Agreement with Ophthotech
RNS
RNS Number : 9024V
Midatech Pharma PLC
13 August 2015

13 August 2015



Midatech Pharma PLC

("Midatech" or the "Company")



Ocular Agreement with Ophthotech



- Development of sustained delivery formulations for rapidly growing ophthalmology market

- Underpins Midatech's financial guidance for 2015



Midatech Pharma (AIM: MTPH), the international specialty pharmaceutical company with a diversified portfolio of high-value products in development, today announced an agreement with Ophthotech Corporation (NASDAQ: OPHT), a biopharmaceutical company specialising in the development of novel therapeutics to treat back of the eye diseases, to explore the feasibility of using Midatech's Q Sphera microencapsulation technology for sustained delivery formulations of select Ophthotech products for the treatment of wet Age-related Macular Degeneration and other ocular indications.



While the financial terms of the agreement are not disclosed ‎the Directors believe that the agreement underpins a significant amount of the market forecasts of revenue for 2015.



Commenting on the collaboration, Dr. Jim Philips, CEO of Midatech Pharma, said: "Drug delivery technology partnering is one of our three core strategies and this agreement with Ophthotech is a perfect fit for Midatech. Using our unique R&D and production facilities in Wales and Spain we will continue, in line with strategy, to generate early revenues to help drive the Group towards financial self-sustainability."



- Ends -

dreamcatcher - 14 Sep 2015 17:37 - 20 of 23

Half Yearly Report
RNS
RNS Number : 8973Y
Midatech Pharma PLC
14 September 2015

14 September 2015



Midatech Pharma PLC

("Midatech" or the "Company")



Interim results for the six months ended 30 June 2015





Midatech Pharma (AIM: MTPH), the international specialty pharmaceutical company with a diversified portfolio of high-value products in development, today announces its interim results for the six months ended 30 June 2015.



Operational Highlights

· Offer, negotiation and agreement to acquire DARA Biosciences Inc. in the US

· Positive results in a proof-of-concept in vivo study for our OpsiSporin sustained release treatment for uveitis

· Approval and site initiation of our Phase IIa transbuccal Insulin (MidaFormTM) clinical trial

· Commissioning of new laboratories and offices at our Head Office site in Abingdon

· Three new collaborations signed

· Commencement of product candidate testing in vivo for glioblastoma



Financial Highlights

· Revenue grew from £36k in the six months to June 2014 to £324k (up 800%)

· Administrative expenses increased from £1,862k in the six months to June 2014 to £3,768k (up 102%)

· Research and development costs increased from £1,260k in the six months to June 2014 to £1,822k (up 45%)

· Net cash outflow from operating activities (before changes in working capital) was £4,983k, up 70% from £2,923k in the six months to June 2014. The cash balance at 30 June 2015 stood at £24.34m.

· Loss per share decreased by 54% from 39p in the six months to June 2014 to 18p



Commenting on the interim results, Dr. Jim Philips, CEO of Midatech Pharma, said: "2015 has shown a strong start to Midatech's next stage of corporate development. With the proposed acquisition of DARA BioSciences, three new collaborations and further progress with our own pipeline, we continue to build upon our strategy with the aim of creating a world-class specialty pharmaceutical company."



Conference call today

Dr Jim Phillips, Chief Executive Officer and Nick Robbins-Cherry, Finance Director, will host a conference call for analysts at 1300 BST today. The conference call ID is: 24926910.

UK: +44 1452 555 566

USA: +1 631 510 7498



A replay of the call will be available for 30 days after the event, using the same conference ID: 24926910.

UK: +44 1452 550 000

USA: +1 866 247 4222



- Ends

Bullshare - 23 Oct 2015 12:53 - 21 of 23

Shares Investor Evenings showcase up to four presentations from leading companies bringing them together in one room for one evening only.

Directors present their latest plans regarding development and growthAn opportunity to talk directly to the companies and personally put forward your questionsThe chance to network with other attendees over drinks and canapés - private investors, wealth managers, private client brokers, fund managers and financial institutions
Who Should Attend?

The evening exposes investors to companies across various sectors. Perfect for existing investors as well as those looking for new investment opportunities.

Date:

Thursday 19th November 2015

Venue:

Novotel Tower Bridge, London EC3N, 10 Pepys Street, London, EC3N 2NR

Event Timings:
18.00 
Registration and coffee
18.30 
Presentations
• David Reading, CEO & Director - Aureus Mining (AUE)
• David Hornsby, CEO - Ideagen (IDEA)
• Dr Jim Phillips, CEO - Midatech Pharma (MTPH)
• Neil Ritson, Chairman - Solo Oil (SOLO)
+ More to be announced
20.30 
Drinks reception and canapés
21.30 
Close
Attendance is free, but spaces are limited. Register now to secure your place!
Aureus Mining (AUE)
Aureus Mining (AUE) 

Aureus Mining Inc, through its subsidiaries, is engaged in the exploration and development of gold deposits in highly prospective and under-explored areas of Liberia and Cameroon. Aureus Mining’s activities are currently concentrated on the development of the New Liberty Gold Project in Liberia. The Company also owns 100% exclusive rights to the Weaju, Gondoja, Ndablama and Leopard Rock projects in Liberia and to the Batouri gold project in Cameroon.

Our Vision is to be an African mid-tier gold producer with a brand recognised for sustainability, innovation and good relationships with the local communities.

Ideagen (IDEA)
Ideagen (IDEA) 

Ideagen Plc is a supplier of compliance based Information Management software with operations in the UK and the United States. We specialise in eGRC (Enterprise Governance, Risk and Compliance) and Healthcare solutions for organisations operating within highly regulated industries. As authors of an excellent portfolio of software products, Ideagen is able to provide complete content lifecycle solutions that enable organisations to meet their Regulatory and Quality Compliance standards, helping them to reduce costs and improve efficiency.

Our Mission Statement is: “To enable our clients to improve their organisations by providing the tools which can help improve customer service, increase efficiency, reduce risk, enhance compliance, and lower costs".

Midatech Pharma (MTPH)
Midatech Pharma (MTPH) 

Midatech is a nanomedicine company focused on the development and commercialisation of multiple, high-value, targeted therapies for major diseases with unmet medical need. It is advancing a pipeline of novel clinical and pre-clinical product candidates based on its proprietary drug conjugate and sustained release delivery platforms with a clear focus on the key therapeutic areas of diabetes, cancer and neuroscience/ophthalmology. Midatech’s strategy is to develop its products in-house in rare cancers and with partners in other indications, and to accelerate growth of its business through strategic acquisition of complementary products and technologies.

Solo Oil (SOLO)
Solo Oil (SOLO) 

Introducing Solo Oil

- Oil and gas Investment company- Listed on the London AiM Market (SOLO)

Objectives

To acquire and develop a diverse global portfolio of oil & gas assets

Portfolio

Non-operated oil & gas assets:

- Major stake in the prolific Ruvuma Basin, Tanzania- Interest in Kiliwani North (KNDL), Tanzania- More than 5 tcf of prospective resources identified in Tanzania- Ntorya-1 (Tanzania) discovery flowed 20 mmscfd and 139 bopd- Participation in UK Weald Basin exploration projects, including Horse Hill- Strategic investment in Burj Africa, West Africa- Enhanced Oil Recovery project in Ontario, Canada

Sponsored by:
AJ Bell Youinvest
London Stock Exchange

Bullshare - 29 Jun 2017 11:37 - 22 of 23

Come and celebrate 6 years of investor evenings with Shares on July 11 and receive a Shares goody bag worth over £150!.

We can’t believe that 6 years have passed since we started our investor evenings, in that time many 1000’s of private investors, fund managers, brokers and analysts have come along and heard from 100’s of listed companies present their investment opportunity.

To celebrate our next investor evening on 11 July in London, we will give all attendees a free goody bag containing:

1)            a one year  subscription to Shares magazine digital. Each week you will receive the latest Shares digital weekly magazine where our team of experts will give you a multitude of investment ideas. You will also gain access to the Shares investor toolkit with live news, LIVE share prices, portfolio and research tools (value £120)

2)            a bottle of champagne (value £20)

3)            The DIY Investor book written by Andy Bell, CEO of AJ Bell (RRP £17.99)

 

On the evening hear from:

MetalNRG (NEX.MNRG) MetalNRG is an NEX Exchange quoted natural resource investing company seeking investments in precious and strategic metals. Metal NRG is reviewing opportunities in various commodities and jurisdictions and anticipates updating the market shortly with regard to its initial target investments. It recently announced its first investing step with the creation of the Palomino Cobalt Project in Western Australia. MetalNRG’s CEO, the well-known resources entrepreneur Paul Johnson (ex-CEO of Metal Tiger), will provide an update on the company’s investment strategy.

Midatech Pharma (MTPH) -  Midatech has a balanced portfolio of fast-growth marketed oncology products and development programmes for its own products, using its proprietary platform technologies to target diseases with unmet medical need.  Midatech offers the potential for rapid revenue growth through its differentiated product portfolio and exciting development pipeline, supported by strong IP and, an ambitious and highly experienced leadership team.

Sphere Medical (SPHR) - Sphere Medical’s vision is to become a leading solution provider to the critical care market offering innovative, frequent on demand, point of care diagnostic and monitoring products to enable closer control of therapeutic response, improve patient outcomes and reduce the overall cost of care. The Company’s strategy is focused on the Proxima platform for measuring blood gases, electrolytes and metabolites. The latest generation of the product, Proxima 4, was launched in December 2016 and is being marketed directly to the critical care market in the UK, Germany, The Netherlands and Belgium, and by distributors in Italy and Spain. 

Xpediator -  Xpediator Plc is expected to IPO on the London Stock Exchange’s AIM market in July 2017. It is a well-established international provider of freight management services operating across the UK and Europe with a particular focus on, and expertise in, the CEE markets. The Group currently employs over 600 people with its operational headquarters in Braintree, England, and country offices in Bulgaria, Lithuania, Estonia, Macedonia, Montenegro, Moldova, Romania and Serbia operating from 22 sites in total.

 

Places at this event are very limited, so register now for your free ticket.

 

Who Should Attend?

The evening is a perfect opportunity for existing shareholders or potential investors to hear from those that matter, the directors running the companies and fund managers managing their fund. Who better to explain the future potential and strategy. 

Date:

Tuesday 11 July 2017

Venue:

Novotel Tower Bridge, London EC3N 2NR, 10 Pepys Street, London, EC3N 2NR

Event Timings:
18.00 
Registration and coffee
18.30 
Presentations
• Paul Johnson, CEO - Metal NRG (MNRG)
• Dr Jim Phillips, CEO - Midatech Pharma (MTPH)
• Dr Wolfgang Rencken, CEO - Sphere Medical (SPHR)
• Stephen Blyth, CEO - Xpediator
+ More to be announced
20.30 
Drinks reception and canapés
21.30 
Close
Metal NRG (MNRG)
Metal NRG (MNRG) Metal NRG is an NEX Exchange quoted natural resource investing company seeking investments in precious and strategic metals.  Metal NRG is reviewing opportunities in various commodities and jurisdictions and anticipates updating the market shortly with regard to its initial target investments.

 

 

Midatech Pharma (MTPH)
Midatech Pharma (MTPH) 

Midatech is a nanomedicine company focused on the development and commercialisation of multiple, high-value, targeted therapies for major diseases with unmet medical need. It is advancing a pipeline of novel clinical and pre-clinical product candidates based on its proprietary drug conjugate and sustained release delivery platforms with a clear focus on the key therapeutic areas of diabetes, cancer and neuroscience/ophthalmology. Midatech’s strategy is to develop its products in-house in rare cancers and with partners in other indications, and to accelerate growth of its business through strategic acquisition of complementary products and technologies.

Sphere Medical (SPHR)
Sphere Medical (SPHR) 

Sphere Medical is a dynamic and growing company specialising in the development of innovative medical monitoring and diagnostic equipment. Their products are used in a wide range of medical applications, enabling faster clinical decision-making and improved patient outcomes, whilst providing efficiencies that result in reduced healthcare costs.

Xpediator
Xpediator 

Xpediator is the holding company for the Group, a well-established international provider of freight management services operating across the UK and Europe with a particular focus on, and expertise in, the CEE markets.

 
he Group currently employs over 600 people with its operational headquarters in Braintree, England, and country offices in Bulgaria, Lithuania, Estonia, Macedonia, Montenegro, Moldova, Romania and Serbia operating from 22 sites in total.
 
The Group has three main business areas which are managed autonomously on a day-to-day basis but directed centrally to cross-sell services to the Group’s customer base:
 
- Freight forwarding, trading under the Delamode brand.
- Logistics and warehousing, trading under the Delamode brand and EMT; and pallet distribution services, trading under the Pall-Ex brand.
- Transport services, trading under the Affinity brand.

 

Sponsored by:
AJ Bell Youinvest
PrimaryBid

Bullshare - 17 Aug 2017 12:22 - 23 of 23

Shares and AJ Bell Media are returning to Edinburgh and will be hosting an Investor Evening where senior board directors from fast growing listed PLCs will make a presentation about their company and update existing & potential investors on their business plans.

During the event and afterwards over drinks, investors will have the chance to discover new investment opportunities and get to know the companies better by talking one on one with the company directors.

The event will take place at the Radisson Blu Hotel, 80 High Street, The Royal Mile, Edinburgh EH11TH.

Corero Network Security (CNS) - Corero Network Security is the leader in real-time, high-performance DDoS defense solutions. Service providers, hosting providers and online enterprises rely on Corero's award winning technology to eliminate the DDoS threat to their environment through automatic attack detection and mitigation, coupled with complete network visibility, analytics and reporting. This next-generation technology provides a First Line of Defense® against DDoS attacks in the most complex environments while enabling a more cost effective economic model than previously available. 

Midatech Pharma (MTPH) - Midatech is a nanomedicine company focused on the development and commercialisation of multiple, high-value, targeted therapies for major diseases with unmet medical need. It is advancing a pipeline of novel clinical and pre-clinical product candidates based on its proprietary drug conjugate and sustained release delivery platforms with a clear focus on the key therapeutic areas of diabetes, cancer and neuroscience/ophthalmology. Midatech’s strategy is to develop its products in-house in rare cancers and with partners in other indications, and to accelerate growth of its business through strategic acquisition of complementary products and technologies.

NEX Exchange - NEX Exchange is used by entrepreneurs and individuals to manage their financial challenges. They give companies of all sizes, from micro to mid-caps, access to a public quote or a fully regulated listing. For investors, they offer simple access to a diverse range of dynamic, small and medium sized companies and to a variety of equity or debt products. For ambitious companies and investors, NEX Exchange is a platform for growth.

Prairie Mining (PDZ) - Prairie Mining is a multi-project coal development company focused on the development and operation of the Jan Karski Mine in the Lublin Coal Basin and the Debiensko Hard Coking Coal Project in Upper Silesia. Located within the heartland of industrial Europe with large scale coal resources and excellent access to infrastructure, Prairie’s vision is to become Europe's lowest cost supplier of premium coal to supply European industry.

Who Should Attend?

The evening exposes investors to companies across various sectors. Perfect for existing investors as well as those looking for new investment opportunities.

Date:

Thursday 21 September 2017

Venue:

Radisson Blu Hotel Edinburgh, 80 High Street, The Royal Mile, Edinburgh, EH11TH

Event Timings:
18.00 
Registration and coffee
18.30 
Presentations
• Dr Jim Phillips, CEO - Midatech Pharma (MTPH)
• Max Raynor, Sales - NEX Exchange
20.30 
Drinks reception and canapés
21.30 
Close
Corero Network Security (CNS)
Corero Network Security (CNS) 

DDoS attacks continue to rise in size, frequency, and com­plexity, impacting the security and availability of the Internet. Service providers and the Internet connected business require automatic protection against this evolving threat landscape.

Corero Network Security is dedicated to improving the security and availability of the Internet through the deployment of innovative DDoS & Network Security Solutions. The Corero SmartWall® Threat Defense System (TDS) family of products can be deployed in various topologies, (in-line or  scrubbing). the SmartWall Threat Defense System (TDS) family of solutions utilizes modern DDoS mitigation architecture to automatically, and surgically remove DDoS attack traffic, while allowing good user traffic to flow uninterrupted.

Midatech Pharma (MTPH)
Midatech Pharma (MTPH) 

Midatech is a nanomedicine company focused on the development and commercialisation of multiple, high-value, targeted therapies for major diseases with unmet medical need. It is advancing a pipeline of novel clinical and pre-clinical product candidates based on its proprietary drug conjugate and sustained release delivery platforms with a clear focus on the key therapeutic areas of diabetes, cancer and neuroscience/ophthalmology. Midatech’s strategy is to develop its products in-house in rare cancers and with partners in other indications, and to accelerate growth of its business through strategic acquisition of complementary products and technologies.

Prairie Mining (PDZ)
Prairie Mining (PDZ) 
Prairie Mining Limited (ASX/LSE/WSE: PDZ) is a multi-project coal development company focused on the development and operation of the Jan Karski Mine in the Lublin Coal Basin and the Debiensko Hard Coking Coal Project in Upper Silesia.
 
Located within the heartland of industrial Europe with large scale coal resources and excellent access to infrastructure, Prairie’s vision is to become Europe's lowest cost supplier of premium coal to supply European industry.
Sponsored by:
AJ Bell Youinvest
NEX Exchange
  • Page:
  • 1
  • 2
Register now or login to post to this thread.